Categoria: Adnkronos News

(Adnkronos) – SHANGHAI, Aug. 16, 2023 /PRNewswire/ — Furniture China 2023 and Maison Shanghai 2023 will be held from September 11-15, 2023, in Shanghai, China. The event, hosted by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., aims to showcase the creativity of "design + life" and promote a new wave of ideal living in the Chinese furniture industry. It will attract over 200,000 professional buyers from 160 countries and cover a vast exhibition area of 300,000 square meters. The theme of the event, "IN NOW!," reflects the rise of the Z-generation as new consumers with diverse living propositions. The event will focus on the new market demand, featuring original design, high-end customization, green intelligence, future office, boutique outdoor, healthy sleep, innovative materials, artistic soft decoration, and creative lighting. The Gold Idea Furniture Design Award (GIDA) will make a comeback at the event, aiming to be a world-class furniture design award in China. The 2023 edition of GIDA will be judged by leading industry experts from around the world. Design plays a crucial role in the event, driving the industry and changing lives. The Design of Designers (DOD) hall will showcase multidimensional design innovations, while Design Q&A will provide design consultancy services. The event will also feature the Genie Award – Aesthetics Space Design Competition. Innovation and change are at the core of the furniture industry's high-quality development. Special exhibitions such as "Office Kitchen" and the Office Future Development Summit Forum will explore the future of the office environment. The event will also feature the Golden Axe Award, recognizing innovation in materials within the home furnishing industry. Digitalization and smart solutions are essential for the industry's future. Furniture China 2023 and Maison Shanghai 2023 combine online and offline platforms to promote precise communication and better connections between supply and demand. The event provides digital services such as customer acquisition, e-commerce development, and digital marketing. Join Furniture China 2023 and Maison Shanghai 2023 to explore the latest trends in home furnishing, connect with industry professionals, and discover innovative design solutions. For more information, visit the official website at https://bit.ly/45qWiVr and sign up at https://bit.ly/3rUniOn. 
View original content:https://www.prnewswire.co.uk/news-releases/furniture-china-2023-and-maison-shanghai-2023-in-now–september-11-15-2023-301900848.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – The National Comprehensive Cancer Network expands materials tailored for the MENA region to help improve patient outcomes by standardizing local cancer care; includes new adaptation focused on genetic/familial cancer risk, as well as care for ovarian/fallopian tube/primary peritoneal cancers. PLYMOUTH MEETING, Pa., Aug. 16, 2023 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced that a library of resources for improving cancer care in the Middle East and North Africa (MENA) has been updated and expanded in collaboration with regional experts. The United States-based non-profit has worked with the King Abdulaziz Medical City in Riyadh, Saudi Arabia, since 2015 to standardize cancer treatment based on the latest evidence and expert-consensus, as part of the MENA-NCCN Regional Coordinating Center. Their efforts have led to the publication of 12 new and updated clinical guidelines covering several cancer presentations. View the new and updated International Adaptations of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) MENA Editions at NCCN.org/global. The NCCN Guidelines® MENA Editions now include up-to-date adaptations for: The guidelines provide color-coded information for health care providers on how to care for people with cancer. Text in black represents current global recommendations, while italicized blue text indicates appropriate and feasible regional modifications—as determined by in-country experts. Approaches that are not currently feasible are marked with grey strikethrough text. "Cancer care for people in the Middle East and North Africa should follow internationally recognized gold standards for clinical direction and policy," explained Kanan Mamdouh Alshammari, MD, Department of Oncology, King Abdulaziz Medical City – Central Region, Ministry of National Guard, Saudi Arabia, Director of the MENA-NCCN Regional Coordinating Center. "Numerous studies have shown how standardizing care results in better outcomes and a more efficient use of resources. These adapted guidelines will enable our local care providers to have access to expert-vetted information on the latest research, but with their specific circumstances in mind." "We are always grateful for the opportunity for knowledge sharing with cancer care experts around the world—allowing us to provide accessible, tailored information to improve cancer outcomes across different regions," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "Our colleagues with the MENA-NCCN Regional Coordinating Center collaborated with us to address the growing need for genetic testing guidance in the Middle East and North Africa as part of our ongoing efforts to make sure everyone, everywhere, has access to the best evidence-based cancer care available." The NCCN Global Program offers numerous free International Adaptations, including European Editions of NCCN Guidelines for Spain and Poland. The NCCN Framework for Resource Stratification (NCCN Framework™) and NCCN Harmonized Guidelines™ provide pragmatic approaches for defining appropriate treatment across different resource levels, particularly in low- and middle-income countries. NCCN resources have been translated into nearly 70 different languages. Learn more at NCCN.org/global. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN
®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation
®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information. Media Contact: Rachel Darwin267-622-6624darwin@nccn.org   Logo – https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg  
View original content:https://www.prnewswire.co.uk/news-releases/new-and-updated-resources-published-to-help-guide-oncology-care-in-the-middle-east-and-north-africa-mena-301900199.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – GENEVA, Aug. 16, 2023 /PRNewswire/ —  MedAlliance has announced completion of patient enrollment in the  SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES). SAVE (Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications) is a prospective multi-center, single-blinded, randomized controlled trial. 84 patients have been randomized to either standard high-pressure balloon angioplasty followed by local application of SELUTION SLR or high-pressure balloon angioplasty with no further lesion treatment. Subjects have been recruited at three sites in Europe and Singapore and are being followed up to 24 months. Endpoints of the study are primary patency at six months with angiographic follow up and freedom from serious adverse events at 30 days. Major secondary endpoints at six months are clinical success, freedom from serious adverse events, late lumen loss and binary vessel restenosis. (clinicaltrials.gov NCT04327609). "We very much look forward to the analysis of the primary endpoint of this important trial at six months, as this is the first prospective randomized trial of a sirolimus-coated balloon in AVF patients with angiographic follow up. Furthermore, we have also measured fistula volume flow rates, which is another key index of failing or maintained fistula function.   I thank MedAlliance for initiating a trial in this difficult patient population" commented Principal Investigator (PI) Dr. Konstantinos Katsanos, MSc, MD, PhD, EBIR, Associate Professor of Interventional Radiology, Patras University Hospital , Patras, Greece. "MedAlliance continues to invest in meaningful clinical trials to evaluate the safety and efficacy of SELUTION SLR in different patient populations", added Jeffrey B. Jump, Chairman and CEO of MedAlliance.  Patients on dialysis rely on  access to receive their treatment: they call this their "lifeline".  An Arteriovenous Fistula (AVF) is considered as the gold standard for hemodialysis access, however it sometimes requires ongoing angioplasty. This is the first randomized study evaluating SELUTION SLR in stenotic lesions in AVF. MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status.  Currently three IDE clinical studies are evaluating SELUTION SLR in the US: in CLTI patients with BTK disease; SFA/PPA; and coronary ISR. In addition, MedAlliance received IDE approval for de novo coronary artery lesions in January 2023. SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe & SELUTION SFA in Japan. MedAlliance's unique DEB technology involves MicroReservoirs which contain a combination of biodegradable polymer intermixed with the anti-restenotic drug sirolimus, applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance's proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon. SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 50,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials. Media Contact: Richard Kenyonrkenyon@medalliance.
com+44 7831 569940 About MedAlliance MedAlliance is medical technology company which announced a staged  acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
 Photo – https://mma.prnewswire.com/media/2185238/MedAlliance_Image.jpgLogo – https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg
   
View original content:https://www.prnewswire.co.uk/news-releases/medalliance-announces-the-completion-of-enrollment-in-save-trial-with-selution-slr-for-treatment-of-av-fistulas-in-renal-dialysis-patients-301899997.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – 35% of suspect games took place in three countries 21% related to First Half Only betting markets LONDON, Aug. 16, 2023 /PRNewswire/ — New data from sports betting integrity specialists Starlizard Integrity Services (SIS) has identified 79 football matches played around the world between 1 January and 30 June 2023 as "suspicious". Of these, 28 (35%) took place in just three countries, with one of those countries accounting for 12 integrity alerts (15%). Matches analysed by SIS are categorised as "suspicious" when they are found to have suspect betting patterns associated with them that may be indicative of match-fixing. While the level of suspicion will vary across matches depending on the nature and amount of evidence discovered, SIS believes that all matches so identified would warrant further investigation. The 79 matches considered "suspicious" in the first half of 2023 represent 0.48% of a total of 16,336 football matches analysed by SIS during the period. This compares with 84 "suspicious" matches (0.45%) from a total of 18,845 games analysed for the same period in 2022.  The SIS 2023 first-six-months data revealed that: Affy Sheikh, Head of Starlizard Integrity Services, commented: "These statistics show that suspicious betting activity and the spectre of match-fixing continue to hang over football – and are not about to go away. The fact that we've seen similar levels of suspicion over the past three years, serves to emphasise that concerted ongoing efforts and stronger collaboration amongst anti-corruption stakeholders are required to tackle this persistent problem in the beautiful game. "The latest data also points to an increase in suspicious activity in more specialised markets, such as First Half Only betting. This highlights the variety of markets in which attempts at match manipulation may occur. Unfortunately, the increase in integrity alerts from lower domestic leagues again demonstrates the vulnerability of those involved in lower-funded leagues and competitions where continued vigilance and education are of upmost importance." About Starlizard Integrity Services Starlizard Integrity Services (SIS) is the specialist integrity division of Starlizard, the London-based sports betting and data consultancy. Starlizard's detailed understanding of sport and sporting performance, as well as its active involvement in betting markets, affords a unique perspective, enabling the company to know better than anyone else in the world when betting markets and sporting contests look wrong. Starlizard has been producing independent integrity services for sports governing bodies and associations since 2010, and established SIS in 2017 as a dedicated resource to focus entirely on this work. Combining its deep insight into how betting markets should behave with detailed on-pitch performance data analysis and research, SIS is ideally placed to identify suspicious matches and betting patterns. For more information, visit www.starlizardintegrity.com
 CONTACT: +44 (0)20 3014 9800, integrity@starlizard.com
 Logo – https://mma.prnewswire.com/media/2185291/SIS_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/starlizard-integrity-services-identifies-79-suspicious-football-matches-played-globally-in-first-half-of-2023-301900760.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – MILAN, Aug. 16, 2023 /PRNewswire/ — TerraPay, a leading global payments infrastructure company, today announced that it has secured authorization as an Electronic Money Institute (EMI) in Italy. Having obtained approval from the Bank of Italy, TerraPay is set to expand its operations within the country and subsequently, throughout the European Union. Under Article 114-quinquies Consolidated Banking Act (TUB), the Bank of Italy authorized TerraPay Italy as an electronic money institution. This holds great significance not only for TerraPay but also for the thriving Italian fintech sector, marking a notable step forward in their respective trajectories. Leveraging its extensive expertise and innovative approach in the digital payments sector, TerraPay aims to positively impact and contribute to the European market. "The commitment of the TerraPay team, supported by the international firm Orrick, was crucial in reaching this historic milestone," stated Ambar Sur, Founder and CEO, TerraPay. "We are excited about what the future holds for us in Italy, and we will continue to work towards providing innovative and secure digital financial services." Commenting on this announcement, Ram Sundaram, Co-Founder, and COO, TerraPay, said, "Securing this authorization firmly establishes TerraPay as a trailblazer in the realm of electronic money within Italy, while also paving the way for exciting avenues of expansion and growth across both the Italian and European markets." TerraPay has established itself as a global partner to leading banks, money transfer operators, mobile wallet operators, and financial institutions to facilitate digital transactions without borders. As a B2B company, TerraPay partners with other businesses and helps them leverage its agile, secure, and scalable technology platform to enhance their customer proposition for remittances, payments, and cross-border spending. The company has an expansive network across 121 receive countries and 208 send countries and is regulated in over 28 countries, globally. The company's key markets include; GCC; North, South, and Central Africa; Europe and SE Asia; Central, North, and South Americas. TerraPay's vision is aligned with achieving the SDG 2030 goal of fostering economic growth and equality, by reducing the cost of transactions across diverse payment channels such as mobile wallets and bank accounts, to name a few. Congratulating the team,Akbar Hussain, Co-Founder, General Counsel & CCO, TerraPay, said "I want to highlight the utmost significance of fostering a resilient regulatory culture within our company. Our collaboration with the Orrick law firm has once again underscored the pivotal role that robust legal support plays in the dynamic landscape of the financial industry." This noteworthy accomplishment was made possible through the concerted efforts of the TerraPay team, which plans to strengthen its presence in Italy and beyond, and the invaluable legal guidance provided by Marco Boldini, a partner at the Orrick law firm, along with his accomplished team consisting of Teresa Mattioni, Niccolò Martinoli, and Niccolo Matteo Bonaldo. Furthermore, on the corporate front, the pivotal contributions of partner Marco dell'Antonia and senior associate Jacopo Taddei were also instrumental in enabling this. TerraPay expresses sincere gratitude for this momentous achievement, as navigating the complex authorization procedures would have been challenging without the support of this team. The company remains optimistic about the outstanding partnership established with the Bank of Italy and the path ahead. About TerraPay Headquartered in the United Kingdom, TerraPay believes that the smallest payment deserves a borderless journey as safe as the largest. The group has been building an ever-expanding payments highway that empowers businesses to create transparent customer experiences with an uninterrupted, secure, and real-time global passage for every payment, however small or large. Registered and regulated across 29 global markets, TerraPay is one of the leading global partners to banks, mobile wallets, money transfer operators, merchants, and financial institutions, creating a more expansive and inclusive international financial ecosystem. With access to an extensive network of 7.5Bn+ bank accounts, 2.1Bn+ mobile wallets, across 121 receive countries and 208 send countries, TerraPay enables its partners to become beacons of the promise of global financial inclusion. Media Contact: Juveria Samrin juveria.n@terrapay.com   Logo: https://mma.prnewswire.com/media/1222771/TerraPay_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/terrapay-group-expands-business-operations-in-italy-and-sets-sights-on-european-union-301899800.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

(Adnkronos) – The Danish biotech company, Tetra Pharm Technologies, announces completion of its new purpose-built headquarters facility to support long-term growth plans. COPENHAGEN, Denmark, Aug. 16, 2023 /PRNewswire/ — Located approx. 40 kilometers north of Copenhagen firmly within Medicon Valley – the leading international life science cluster spanning the Greater Copenhagen region and southern Sweden – the newly established 4,000 sqm facility represents a significant milestone in Tetra Pharm Technologies' journey of planned growth and expansion. Former manufacturing site of medical solutions company Ambu A/S, the facility has undergone extensive construction and building upgrades to accommodate the specific needs of Tetra Pharm Technologies to enlarge its manufacturing capacity, bolster and streamline its production capabilities, and provide an optimal environment for the company's ambitious R&D activities. "As a pharmaceutical company committed to improve quality of life for our patients, moving into this state-of-the-art headquarters facility is a momentous occasion. The new site empowers us to elevate our research and development efforts, expand and improve operational efficiency, and ultimately, enhance the accessibility of our innovative pharmaceutical drugs to patients as part of our market expansion", says Martin Rose, CEO, Tetra Pharm Technologies. The spacious facility provides Tetra Pharm Technologies with the opportunity to cultivate a dynamic and collaborative work environment for its valued employees enabling cross-functional teams to collaborate seamlessly. Tetra Pharm Technologies will continue operating its existing manufacturing and production facility, located in Hillerød. The original facility will transition into a dedicated pilot plant allowing the company to conduct thorough tests, trials, and evaluations without interfering with the operations at its new headquarters facility. Martin Rose, CEO, Tetra Pharm Technologies, added, "We recognize the immense value of our original manufacturing and production site, which has been the birthplace of our company. Retaining it as a test site will enable us to preserve our strong focus on scientific innovation for the ultimate benefit of our patients." About Tetra Pharm Technologies Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu
 For further information:Martin Caspersencap@tetrapharm.eu+45 61224241 Photo – https://mma.prnewswire.com/media/2184861/Tetra_Pharm_Technologies_Site_OL.jpgLogo – https://mma.prnewswire.com/media/2184862/TPT_Logo.jpg
         
View original content:https://www.prnewswire.co.uk/news-releases/tetra-pharm-technologies-inaugurates-new-rd-manufacturing-and-production-facility-301899619.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)